Interleukin 23

WikiDoc Resources for Interleukin 23
Articles
Most recent articles on Interleukin 23 Most cited articles on Interleukin 23 Review articles on Interleukin 23 Articles on Interleukin 23 in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Interleukin 23 Images of Interleukin 23 Photos of Interleukin 23 Podcasts & MP3s on Interleukin 23 Videos on Interleukin 23
Evidence Based Medicine
Cochrane Collaboration on Interleukin 23 Bandolier on Interleukin 23 TRIP on Interleukin 23
Clinical Trials
Ongoing Trials on Interleukin 23 at Clinical Trials.gov Trial results on Interleukin 23 Clinical Trials on Interleukin 23 at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Interleukin 23 NICE Guidance on Interleukin 23 NHS PRODIGY Guidance FDA on Interleukin 23 CDC on Interleukin 23
Books
Books on Interleukin 23
News
Interleukin 23 in the news Be alerted to news on Interleukin 23 News trends on Interleukin 23
Commentary
Blogs on Interleukin 23
Definitions
Definitions of Interleukin 23
Patient Resources / Community
Patient resources on Interleukin 23 Discussion groups on Interleukin 23 Patient Handouts on Interleukin 23 Directions to Hospitals Treating Interleukin 23 Risk calculators and risk factors for Interleukin 23
Healthcare Provider Resources
Symptoms of Interleukin 23 Causes & Risk Factors for Interleukin 23 Diagnostic studies for Interleukin 23 Treatment of Interleukin 23
Continuing Medical Education (CME)
CME Programs on Interleukin 23
International
Interleukin 23 en Espanol Interleukin 23 en Francais
Business
Interleukin 23 in the Marketplace Patents on Interleukin 23
Experimental / Informatics
List of terms related to Interleukin 23

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Interleukin-23 (IL-23) is a heterodimeric cytokine consisting of two subunits, one called p40, which is shared with another cytokine, IL-12, and another called p19 (the IL-23 alpha subunit). IL-23 is an important part of the inflammatory response against infection. It promotes upregulation of the matrix metalloprotease MMP9, increases angiogenesis and reduces CD8+ T-cell infiltration. Recently, IL-23 has been implicated in the development of cancerous tumors. In conjunction with IL-6 and TGF-β1, IL-23 stimulates naive CD4+ T cells to differentiate into a novel subset of cells called Th17 cells, which are distinct from the classical Th1 and Th2 cells. Th17 cells produce IL-17, a proinflammatory cytokine that enhances T cell priming and stimulates the production of proinflammatory molecules such as IL-1, IL-6, TNF-alpha, NOS-2, and chemokines resulting in inflammation. Knockout mice deficient in either p40 or p19, or in either subunit of the IL-23 receptor (IL-23R and IL12R-β1) develop less severe symptoms of multiple sclerosis and inflammatory bowel disease highlighting the importance of IL-23 in the inflammatory pathway. Entheseal-resident T cells are sensitive to IL-23 overexpression and they respond vigorously by releasing IL-17 and IL-22 which lead to local inflammatory changes and osteoblast-mediated bone remodeling. These T cells are also present in the aortic root and valve, leading to aortitis that may be seen in patients with ankylosing spondylitis.

See also

• CNTO 1275